Congenital Disorders of Glycosylation
Glycomine Inc. focuses on PMM2-CDG, a rare inherited metabolic disorder affecting protein glycosylation and multiple organ systems.
- PMM2-CDG
- Inherited metabolic disease
- Glycosylation defects
The sponsor’s clinical activity centers on this ultra-rare disease area, with research spanning pediatric, adolescent, and adult populations.
Neurological Manifestations
Its trials place particular emphasis on ataxia and related neurological impairment associated with PMM2-CDG.
- Ataxia assessment
- Neuromotor function
- Clinical severity measures
Clinical evaluation in this area reflects interest in motor coordination and disease-related functional limitations.
Rare Disease Therapeutics
Glycomine Inc. is actively involved in therapeutic development for rare genetic disorders, with a strong focus on treatment options for PMM2-CDG.
- Rare disease treatment
- Genetic disorder therapy
- Long-term disease management
Its research portfolio includes ongoing studies evaluating safety, tolerability, and clinical effects in this specialized therapeutic setting.
Metabolic and Multisystem Disease Care
The sponsor’s studies also reflect interest in the broader systemic consequences of PMM2-CDG, a disorder that can affect neurological and metabolic function together.
- Multisystem involvement
- Metabolic disease
- Functional outcome monitoring
Research activity in this area supports clinical understanding of disease burden across different age groups and care settings.
